BGLC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioNexus Gene Lab Corp (BGLC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows no significant positive trading signals, lacks recent news catalysts, and has weak financial performance. Given the neutral technical indicators and absence of compelling reasons to invest immediately, it is better to hold off for now.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 56.213, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 2.515, with key resistance at 2.692 and support at 2.338.
Gross margin increased by 19.66% YoY, showing some operational improvement.
No recent news or significant trading trends from hedge funds or insiders. Stock trend analysis suggests a potential short-term decline.
In Q3 2025, revenue decreased to $2,543,823 (-3.29% YoY), net income dropped to -$708,991 (-47.30% YoY), and EPS fell to -0.39 (-48.00% YoY). However, gross margin improved to 14.85% (+19.66% YoY).
No data available on analyst ratings or price target changes.
